vTv Therapeutics to Participate in Upcoming May Investor Conferences

Stock Information for vTv Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About vTv Therapeutics Inc.

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.